Palisade Bio Stock Performance
| PALI Stock | USD 1.49 0.12 7.45% |
The company holds a Beta of 1.23, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Palisade Bio will likely underperform. Palisade Bio right now holds a risk of 7.14%. Please check Palisade Bio treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to decide if Palisade Bio will be following its historical price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Palisade Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong essential indicators, Palisade Bio is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Last Split Factor 1:15 | Dividend Date 2019-07-18 | Last Split Date 2024-04-08 |
1 | Palisade Bio Approves Key Proposals at Stockholder Meeting - TipRanks | 12/04/2025 |
2 | Palisade Bio Stock Surge Whats Behind the Rise - StocksToTrade | 12/10/2025 |
3 | Palisade Bio Upgraded to Buy Heres What You Should Know | 12/19/2025 |
4 | Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 | 12/30/2025 |
5 | Palisade Bio soars 5 percent ahead of clinical trial results - MSN | 01/06/2026 |
6 | B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com | 01/08/2026 |
7 | Palisade Bio director Williams buys 9,400 in shares - Investing.com | 01/13/2026 |
8 | Acquisition by Williams Donald Allen of 5000 shares of Palisade Bio at 1.6712 subject to Rule 16b-3 | 01/16/2026 |
9 | Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board | 01/29/2026 |
Palisade Bio Relative Risk vs. Return Landscape
If you would invest 168.00 in Palisade Bio on November 5, 2025 and sell it today you would lose (19.00) from holding Palisade Bio or give up 11.31% of portfolio value over 90 days. Palisade Bio is currently generating 0.0495% in daily expected returns and assumes 7.1386% risk (volatility on return distribution) over the 90 days horizon. In different words, 64% of stocks are less volatile than Palisade, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Palisade Bio Target Price Odds to finish over Current Price
The tendency of Palisade Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.49 | 90 days | 1.49 | about 98.0 |
Based on a normal probability distribution, the odds of Palisade Bio to move above the current price in 90 days from now is about 98.0 (This Palisade Bio probability density function shows the probability of Palisade Stock to fall within a particular range of prices over 90 days) .
Palisade Bio Price Density |
| Price |
Predictive Modules for Palisade Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Palisade Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Palisade Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Palisade Bio is not an exception. The market had few large corrections towards the Palisade Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Palisade Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Palisade Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.04 | |
β | Beta against Dow Jones | 1.23 | |
σ | Overall volatility | 0.22 | |
Ir | Information ratio | 0.01 |
Palisade Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Palisade Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Palisade Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Palisade Bio had very high historical volatility over the last 90 days | |
| Palisade Bio may become a speculative penny stock | |
| Palisade Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (14.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Palisade Bio currently holds about 5 M in cash with (12.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23. | |
| Palisade Bio has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board |
Palisade Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Palisade Stock often depends not only on the future outlook of the current and potential Palisade Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Palisade Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.4 M | |
| Cash And Short Term Investments | 9.8 M |
Palisade Bio Fundamentals Growth
Palisade Stock prices reflect investors' perceptions of the future prospects and financial health of Palisade Bio, and Palisade Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Palisade Stock performance.
| Return On Equity | -2.29 | ||||
| Return On Asset | -0.88 | ||||
| Current Valuation | 235.2 M | ||||
| Shares Outstanding | 149 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 69.49 X | ||||
| Price To Sales | 14.03 X | ||||
| EBITDA | (14.42 M) | ||||
| Net Income | (14.44 M) | ||||
| Cash And Equivalents | 5 M | ||||
| Cash Per Share | 0.23 X | ||||
| Total Debt | 169 K | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 2.59 X | ||||
| Book Value Per Share | 0.35 X | ||||
| Cash Flow From Operations | (12.19 M) | ||||
| Earnings Per Share | (2.07) X | ||||
| Market Capitalization | 222.31 M | ||||
| Total Asset | 10.88 M | ||||
| Retained Earnings | (135.94 M) | ||||
| Working Capital | 7.26 M | ||||
About Palisade Bio Performance
By evaluating Palisade Bio's fundamental ratios, stakeholders can gain valuable insights into Palisade Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Palisade Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Palisade Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.19) | (1.25) | |
| Return On Capital Employed | (1.75) | (1.84) | |
| Return On Assets | (1.19) | (1.25) | |
| Return On Equity | (2.22) | (2.33) |
Things to note about Palisade Bio performance evaluation
Checking the ongoing alerts about Palisade Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Palisade Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Palisade Bio had very high historical volatility over the last 90 days | |
| Palisade Bio may become a speculative penny stock | |
| Palisade Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (14.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Palisade Bio currently holds about 5 M in cash with (12.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23. | |
| Palisade Bio has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board |
- Analyzing Palisade Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Palisade Bio's stock is overvalued or undervalued compared to its peers.
- Examining Palisade Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Palisade Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Palisade Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Palisade Bio's stock. These opinions can provide insight into Palisade Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Palisade Stock analysis
When running Palisade Bio's price analysis, check to measure Palisade Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Palisade Bio is operating at the current time. Most of Palisade Bio's value examination focuses on studying past and present price action to predict the probability of Palisade Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Palisade Bio's price. Additionally, you may evaluate how the addition of Palisade Bio to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |